This means that passive immunization with tau antibodies is a practical therapeutic target and which the CSF volume of p-tau262/356 or from the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to observe tau therapeutics in clinical trials. They shown this romantic